SG11202111132WA - Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one - Google Patents

Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Info

Publication number
SG11202111132WA
SG11202111132WA SG11202111132WA SG11202111132WA SG11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA SG 11202111132W A SG11202111132W A SG 11202111132WA
Authority
SG
Singapore
Prior art keywords
chloro
diazacyclotetradecin
metheno
pyrazolo
hexahydro
Prior art date
Application number
SG11202111132WA
Other languages
English (en)
Inventor
Nicolas Cuniere
Yu Fan
Sergei Kolotuchin
Subha Mukherjee
Eric M Simmons
Amarjit Singh
Carolyn S Wei
Yi Xiao
Changxia Yuan
Bin Zheng
Simon Albert Wagschal
Diego Fernando Domenico Broggini
Duy Chi Trung Cao
Kostiantyn Chernichenko
Sébastien François Emmanuel LEMAIRE
Ηαϊμ Cyril Ben
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of SG11202111132WA publication Critical patent/SG11202111132WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202111132WA 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one SG11202111132WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832614P 2019-04-11 2019-04-11
PCT/US2020/027655 WO2020210613A1 (fr) 2019-04-11 2020-04-10 Nouvelles options synthétiques pour la fabrication de (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl) phényl]-6-oxo-1(6h)-pyrimidinyl}1-(difluorométhyl)-6-méthyl-1,4,7,8,9,10-hexahydro-11,15- (metheno)pyrazolo [4,3-b] [1,7] diazacyclotétradecin-5 (6h)-one

Publications (1)

Publication Number Publication Date
SG11202111132WA true SG11202111132WA (en) 2021-11-29

Family

ID=70457148

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111132WA SG11202111132WA (en) 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Country Status (16)

Country Link
US (1) US20220144836A1 (fr)
EP (2) EP3953334B1 (fr)
JP (1) JP2022526659A (fr)
KR (1) KR20220045105A (fr)
CN (1) CN114375290A (fr)
AR (1) AR118649A1 (fr)
AU (1) AU2020272973A1 (fr)
BR (1) BR112021020368A2 (fr)
CA (1) CA3132365A1 (fr)
EA (1) EA202192807A1 (fr)
ES (1) ES2969253T3 (fr)
IL (1) IL287102A (fr)
MX (1) MX2021012286A (fr)
SG (1) SG11202111132WA (fr)
TW (1) TW202104188A (fr)
WO (1) WO2020210613A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4133064A2 (fr) 2020-04-10 2023-02-15 Codexis, Inc. Polypeptides de transaminase modifiés
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830234A1 (fr) * 2011-03-15 2012-09-20 Abbvie Inc. Modulateurs des recepteurs hormonaux nucleaires
WO2015116886A1 (fr) 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Macrocycles à groupes hétérocycliques p2' servant d'inhibiteurs du facteur xia
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (fr) * 2014-10-01 2018-10-20
CN105294496A (zh) * 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法
WO2018133793A1 (fr) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 Inhibiteur du facteur xia de coagulation sanguine et ses utilisations
EP3957638A4 (fr) * 2019-04-16 2023-01-11 China Resources Biopharmaceutical Company Limited Dérivés macrocycliques agissant comme inhibiteur du facteur xia
WO2021013209A1 (fr) * 2019-07-23 2021-01-28 南京明德新药研发有限公司 Dérivés macrocycliques en tant qu'inhibiteurs du facteur xia
EP4133065A1 (fr) * 2020-04-10 2023-02-15 Codexis, Inc. Polypeptides de carboxyestérase pour résolution cinétique

Also Published As

Publication number Publication date
US20220144836A1 (en) 2022-05-12
EP4234555A2 (fr) 2023-08-30
CN114375290A (zh) 2022-04-19
EA202192807A1 (ru) 2022-02-24
JP2022526659A (ja) 2022-05-25
WO2020210613A1 (fr) 2020-10-15
ES2969253T3 (es) 2024-05-17
AR118649A1 (es) 2021-10-20
MX2021012286A (es) 2022-04-06
CA3132365A1 (fr) 2020-10-15
EP4234555A3 (fr) 2024-01-03
EP3953334A1 (fr) 2022-02-16
BR112021020368A2 (pt) 2021-12-07
TW202104188A (zh) 2021-02-01
EP3953334B1 (fr) 2023-11-22
IL287102A (en) 2021-12-01
AU2020272973A1 (en) 2021-12-02
KR20220045105A (ko) 2022-04-12

Similar Documents

Publication Publication Date Title
IL287102A (en) New synthetic possibilities towards the production of (6r, 10s) -10- {4- [5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl) phenyl] -6-oxo -1 (6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo [4,3-b] [1 , 7 ] diazacyclotetradecin-5 (6h)-one
IL291471A (en) Pyrimido[3,2-d]pyrimidine compounds as immunomodulators
IL308438A (en) Pyrido[3,4-D]pyrimidine compounds inhibit mutant KRAS proteins
MX2021011438A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.
ZA202204206B (en) Pesticidally active fused bicyclic heteroaromatic compounds
SI1725544T1 (sl) 3-(4-heterociklil-1,2,3-triazol-1-il)-N-aril-benzamidi kot inhibitorji proizvodnje citokinov za zdravljenje kroničnih vnetnih bolezni
FI3689865T3 (fi) Uusia aminopyrimidiinijohdannaisia
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
JP2014513139A5 (fr)
EP3997087A4 (fr) Composés bicycliques hétéroaromatiques fusionnés substitués utilisés en tant qu'inhibiteurs de kinase et leur utilisation
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
ZA202101735B (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
MX2017015257A (es) Cristal de (6s, 9as)-n-bencil-8-({6-[3-(4-etilpiperazin-1-il)azeti din-1-il]piridin-2-il}metil)-6-(2-(fluoruro-4-hidroxibencil)-4,7- dioxo-2-prop-2-en-1-il)hexahidro-2h-pirazino[2,1-c] [1,2,4]triazon-1-(6h)-carboxamida.
ZA201002214B (en) 3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
NZ629411A (en) Treatment of cancer with dihydropyrazino-pyrazines
MX2021012849A (es) Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak.
IL273396A (en) 4-[[(7-aminopyrazolo[5,1-A]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
IL289456A (en) 4-oxo-4,3-dihydropyrido[4,3-d] pyrimidine compounds inhibit eif4e
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
MX2020002505A (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso.
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2008000079A (es) Derivados de quinolina como agentes antibacterianos.
IL291721A (en) 5-bromo-2'6-d1(1h-pyrsol-1-yl)pyrimidine-4-amine and new salts
WO2020089687A3 (fr) Dérivés de benzodiazépine hétérocycliques fusionnés et leurs utilisations
CO2023005883A2 (es) Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona